Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Sudhir Agrawal, D. Phil., Chief Executive Officer of Idera will present at the 25th Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2013 at 3:00 p.m. EST at the New York Palace Hotel in New York City.
A live audio webcast of the presentation will be available in the Investors and Media section of Idera's website at www.iderapharma.com or at the link http://www.media-server.com/m/p/c8zsyhqf. An archived version will also be available on the Company's website after the event for 90 days.
About Idera Pharmaceuticals, Inc.
Idera's technology platform involves creating novel synthetic RNA- and DNA-based compounds to modulate immune responses. Idera has applied this platform to develop proprietary Toll-like receptor (TLR) antagonists as immunomodulatory drug candidates. Toll-like receptor antagonists block the over-activation of immune factors which can cause a range of pathological effects. Idera is conducting clinical development of TLR antagonists in autoimmune and inflammatory diseases, and preclinical development of their use in certain genetically defined forms of B-cell lymphoma. More information on Idera is available at www.iderapharma.com.Source: Idera Pharmaceuticals, Inc.